Average Insider

Where insiders trade, we follow

$NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Healthcare
Sector
Drug Manufacturers - Specialty & Generic
Industry
Kyle W. Gano
CEO
1800
Employees
$156.59
Current Price
$12.82B
Market Cap
52W Low$122.14
Current$156.5953.8% above low, 46.2% below high
52W High$186.12

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells14$2,473,030.0115,000
2 weeksBuys00--All Sells
Sells14$2,473,030.0115,000
1 monthBuys00--All Sells
Sells216$4,809,011.7130,000
2 monthsBuys00--All Sells
Sells216$4,809,011.7130,000
3 monthsBuys00--All Sells
Sells519$5,635,377.0235,291
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 17, 2026
LYONS GARY A
Director
Sale4,100$165.90$680,176.88View Details
Nov 17, 2026
LYONS GARY A
Director
Sale1,200$163.11$195,732.72View Details
Nov 17, 2026
LYONS GARY A
Director
Sale4,011$163.94$657,555.32View Details
Nov 17, 2026
LYONS GARY A
Director
Sale5,689$165.15$939,565.09View Details
Nov 3, 2026
MORROW GEORGE J
Director
Sale1,226$164.74$201,971.49View Details
Oct 30, 2026
MORROW GEORGE J
Director
Sale300$149.00$44,700.00View Details
Nov 2, 2026
MORROW GEORGE J
Director
Sale1,300$146.76$190,783.06View Details
Nov 3, 2026
MORROW GEORGE J
Director
Sale100$158.18$15,818.00View Details
Nov 3, 2026
MORROW GEORGE J
Director
Sale100$162.05$16,205.00View Details
Nov 3, 2026
MORROW GEORGE J
Director
Sale1,500$167.72$251,587.20View Details
Nov 3, 2026
MORROW GEORGE J
Director
Sale908$165.71$150,461.05View Details
Nov 3, 2026
MORROW GEORGE J
Director
Sale1,466$166.77$244,491.86View Details
Nov 2, 2026
MORROW GEORGE J
Director
Sale1,900$144.98$275,452.69View Details
Nov 3, 2026
MORROW GEORGE J
Director
Sale600$163.71$98,224.98View Details
Nov 2, 2026
MORROW GEORGE J
Director
Sale4,300$145.86$627,194.13View Details
Nov 3, 2026
MORROW GEORGE J
Director
Sale1,300$168.53$219,092.25View Details
Sep 14, 2026
Boyer David W.
Chief Corp. Affairs Officer
Sale826$157.45$130,050.56View Details
Sep 14, 2026
ABERNETHY MATT
Chief Financial Officer
Sale2,311$157.20$363,284.81View Details
Sep 9, 2026
BENEVICH ERIC
Chief Commercial Officer
Sale2,154$154.61$333,029.94View Details
35 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Oct 27, 2026
EPS
Estimated$1.91
ActualN/A
Revenue
Estimated$1.04B
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1